120 related articles for article (PubMed ID: 8996572)
1. Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients.
Kaul S; Srinivas NR; Mummaneni V; Igwemezie LN; Barbhaiya RH
Semin Oncol; 1996 Dec; 23(6 Suppl 13):23-9. PubMed ID: 8996572
[TBL] [Abstract][Full Text] [Related]
2. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
3. A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
Kaul S; Srinivas NR; Igwemezie LN; Barbhaiya RH
Semin Oncol; 1996 Dec; 23(6 Suppl 13):15-22. PubMed ID: 8996571
[TBL] [Abstract][Full Text] [Related]
4. Early studies of etoposide phosphate, a water-soluble prodrug.
Budman DR
Semin Oncol; 1996 Dec; 23(6 Suppl 13):8-14. PubMed ID: 8996570
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
[TBL] [Abstract][Full Text] [Related]
6. Clinical studies with etoposide phosphate.
Greco FA; Hainsworth JD
Semin Oncol; 1996 Dec; 23(6 Suppl 13):45-50. PubMed ID: 8996575
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.
Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH
Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors.
Kreis W; Budman DR; Vinciguerra V; Hock K; Baer J; Ingram R; Schacter LP; Fields SZ
Cancer Chemother Pharmacol; 1996; 38(4):378-84. PubMed ID: 8674162
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
Dorr RT; Briggs A; Kintzel P; Meyers R; Chow HH; List A
Bone Marrow Transplant; 2003 Apr; 31(8):643-9. PubMed ID: 12692603
[TBL] [Abstract][Full Text] [Related]
12. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
13. Etoposide phosphate: what, why, where, and how?
Schacter L
Semin Oncol; 1996 Dec; 23(6 Suppl 13):1-7. PubMed ID: 8996569
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.
Braybrooke JP; Levitt NC; Joel S; Davis T; Madhusudan S; Turley H; Wilner S; Harris AL; Talbot DC
Clin Cancer Res; 2003 Oct; 9(13):4682-8. PubMed ID: 14581337
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of etoposide phosphate plus paclitaxel.
Brooks DJ; Alberts DS
Semin Oncol; 1996 Dec; 23(6 Suppl 13):30-3. PubMed ID: 8996573
[TBL] [Abstract][Full Text] [Related]
16. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer.
Doyle JJ; Dezii CM; Sadana A
Semin Oncol; 1996 Dec; 23(6 Suppl 13):51-60. PubMed ID: 8996576
[TBL] [Abstract][Full Text] [Related]
17. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity.
Collier K; Schink C; Young AM; How K; Seckl M; Savage P
J Oncol Pharm Pract; 2008 Mar; 14(1):51-5. PubMed ID: 18337441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
